Companies

Sanofi

5 articles

Industry NewsSeawolf Therapeutics / SanofiBioSpace

Seawolf Launches With $100M and a $1.2B Sanofi Deal for Redosable DNA Medicines

  • Seawolf Therapeutics raised a $100M Series A from Versant, Novartis Venture Fund, Lilly, CRISPR Therapeutics and others.
  • Its Trident platform delivers DNA payloads in redosable lipid nanoparticles, claimed to last longer than RNA-LNP therapies with similar potency and safety.
  • Sanofi signed a multi-target research and licensing deal worth up to $1.2B in milestones plus royalties, covering bleeding disorders and other indications.
PointsBased on public reports

Non-viral DNA delivery that can be redosed would sidestep the immunity and dosing limits of AAV, so a Sanofi deal plus Lilly and Novartis money is a notable vote. But the support is animal data only, and the lead program and targets are undisclosed. Compare it against durable RNA-LNP editing and Sanofi's own hemophilia pipeline before reading too much into the headline figure, since milestones dwarf the upfront.

Industry NewsSanofi / Nurix TherapeuticsBioPharma Dive

Sanofi Drops Nurix's Oral STAT6 Degrader After New Nonclinical Eczema Findings

  • Sanofi has discontinued SAR448272, the oral STAT6 degrader it licensed from Nurix; Sanofi pointed to new nonclinical findings in eczema models and said it still values the STAT6 pathway.
  • The 2020 collaboration carried $55 million upfront and up to $2.5 billion in potential payments; Sanofi exercised its option last year and paid a $10 million milestone when Phase 1 began in August.
  • Nurix shares fell more than 40%, though analysts said its lead asset, bexobrutideg (partnered with Roche), is unaffected.
PointsBased on public reports

Nobody outside the two companies can say what the nonclinical signal was, which is the real problem: a safety or tolerability finding in a degrader would rewrite the read-across, while a molecule-specific flaw would not. Kymera's STAT6 degrader, with a mid-stage readout due, is now the class test, and Sanofi's second STAT6 programme with Recludix shows it is not walking away from the target. Watch whether Nurix retains rights.

Industry NewsSanofiBioSpace

Sanofi Raises Guidance, Then Says It Wants Late-Stage and Commercial Deals to Cover the Dupixent Cliff

  • Third-quarter sales beat consensus and Sanofi lifted full-year growth guidance to the low teens at constant currency, helped by Dupixent, which grew by about a third and made up roughly 39% of sales.
  • Management said cash flow will fund business development focused on de-risked, late-stage and commercial assets that suit its sales organization, plus smaller bolt-ons for early pipeline, including from China.
  • Earlier this year the CFO put capacity at up to €15 billion for R&D deals, with room for up to €10 billion more on a commercial purchase.
PointsBased on public reports

Dupixent exclusivity runs to 2031, but Sanofi is shopping now from a position of strength, which is the cheapest time to do it. Preferring de-risked assets means paying for certainty, so expect competitive bidding for late-stage immunology and I&I. The China bolt-on comment is the quieter signal: early pipeline will keep coming from licensing, not from internal discovery.

Industry NewsSanofiSTAT News

Sanofi settles EU antitrust probe over disparaging a rival flu vaccine, no fine

  • EU antitrust regulators accepted concessions from Sanofi to close a probe into an allegedly misleading campaign that disparaged a rival flu vaccine.
  • Because the case ended on accepted commitments, Sanofi avoids a fine.
  • Details of the commitments are behind STAT's paywall; this summary rests on the public excerpt only.
PointsBased on public reports

A commitments decision is the cheap exit: no infringement finding, no fine, and little disruption to the flu franchise's commercial playbook. The wider signal is that regulators are watching comparative vaccine messaging, so rivals' medical-affairs and marketing teams will likely be more careful about how they position products against competitors.

Industry NewsSanofi / RegeneronFierce Biotech

Sanofi Pays Regeneron $1B Upfront to Add Four Long-Acting Immunology Antibodies to the Dupixent Alliance

  • Sanofi and Regeneron expanded their alliance with $1 billion upfront and up to $7 billion in development, regulatory and commercial milestones.
  • The deal adds four antibodies: clinical-stage long-acting IL-13 REGN20423, a long-acting IL-4xIL-13 bispecific and two preclinical long-acting antibodies against IL-4 pathway targets.
  • Regeneron leads R&D, Sanofi leads global commercialization, and costs and profits split 50:50.
PointsBased on public reports

This is Sanofi buying a Dupixent successor from the one partner that already knows how to make that franchise work, ahead of the 2031 US patent expiry. Paying $1B for a Phase 1 antibody and three preclinical ones is really a bet on long-acting dosing as the differentiator against a crowded type 2 inflammation field. For Regeneron it is non-dilutive funding plus a reconfirmed partner; I'd watch whether Sanofi's other immunology assets get de-prioritized.